- Home
- NAT vs TRML Comparison
NAT vs TRML Comparison
Compare NAT & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- TRML
- Stock Information
- Founded
- NAT 1995
- TRML 2021
- Country
- NAT Bermuda
- TRML United States
- Employees
- NAT N/A
- TRML N/A
- Industry
- NAT Marine Transportation
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- NAT Consumer Discretionary
- TRML Health Care
- Exchange
- NAT Nasdaq
- TRML Nasdaq
- Market Cap
- NAT 534.5M
- TRML 509.8M
- IPO Year
- NAT 1997
- TRML N/A
- Fundamental
- Price
- NAT $2.50
- TRML $14.45
- Analyst Decision
- NAT Hold
- TRML Strong Buy
- Analyst Count
- NAT 2
- TRML 6
- Target Price
- NAT $3.50
- TRML $45.20
- AVG Volume (30 Days)
- NAT 2.9M
- TRML 360.6K
- Earning Date
- NAT 02-28-2025
- TRML 03-13-2025
- Dividend Yield
- NAT 13.71%
- TRML N/A
- EPS Growth
- NAT N/A
- TRML N/A
- EPS
- NAT 0.22
- TRML N/A
- Revenue
- NAT $225,096,000.00
- TRML N/A
- Revenue This Year
- NAT $21.35
- TRML $363.93
- Revenue Next Year
- NAT $4.61
- TRML N/A
- P/E Ratio
- NAT $11.03
- TRML N/A
- Revenue Growth
- NAT N/A
- TRML N/A
- 52 Week Low
- NAT $2.39
- TRML $11.87
- 52 Week High
- NAT $4.40
- TRML $29.79
- Technical
- Relative Strength Index (RSI)
- NAT 43.63
- TRML 41.51
- Support Level
- NAT $2.44
- TRML $16.39
- Resistance Level
- NAT $2.64
- TRML $17.36
- Average True Range (ATR)
- NAT 0.07
- TRML 1.03
- MACD
- NAT -0.00
- TRML -0.21
- Stochastic Oscillator
- NAT 20.17
- TRML 3.46
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters pursuant to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.